Review





Similar Products

99
Developmental Studies Hybridoma Bank mouse igg2b myosin heavy chain type i antibody
Inhibition of VEGFR signaling blocks increased endurance exercise capacity by SAAR (A) Fold changes of transcripts associated with Vegf signaling using transcriptomic dataset presented in in muscles of male mice ( n = 6) after sulfur amino acid restriction (SAAR) compared with control (Con) diet for seven days. (B) Normalized count values of Vegfb in EDL and soleus from bulk RNA sequencing ( n = 6) of male mice given ad libitum access to SAAR versus Con diet on day seven using transcriptomic dataset presented in . (C) Normalized count values of Flt1 in EDL and soleus from bulk RNA sequencing ( n = 6) of male mice given ad libitum access to SAAR versus Con diet on day seven using transcriptomic dataset presented in . (D) Experimental set up and color scheme used in E, 5F, C, and S5D. (E) Percent change in body weight ( n = 16–24) of male mice treated with vehicle (veh) or axitinib via oral gavage in combination with ad libitum access to SAAR versus Con diet after seven days. (F) Distance ran during a one-time maximal endurance test ( n = 16–24) of male mice treated with veh or axitinib via oral gavage in combination with ad libitum access to SAAR versus Con diet for seven days. (G) Representative fluorescence images of IB4 (white) staining in EDL cross sections of mice fed a Con or SAAR Diet, co-treated with veh or axitinib via oral gavage (scale bar, 400 μm) for seven days (n = 5–8). (H) Normalized count values of Flt1 in EDL treated with either veh or axitinib from bulk RNA sequencing ( n = 5) of male mice given ad libitum access to SAAR versus Con diet on day seven. (I) Normalized count values of Kdr in EDL treated with either veh or axitinib from bulk RNA sequencing ( n = 5) of male mice given ad libitum access to SAAR versus Con diet on day seven. (J) Experimental set up and color scheme used in K, 5L, J, and S5K. (K) Percent change in body weight (n = 8–10) of male mice treated with <t>IgG</t> or DC101 via i.p. injection every other day in combination with ad libitum access to SAAR versus Con diet after seven days. (L) Distance ran during a one-time maximal endurance test ( n = 12–16) of male mice treated with IgG or DC101 via i.p. injection every other day in combination with ad libitum access to SAAR versus Con diet on day seven. A-C, E, G-I, represent data from mice that were not subjected to endurance running; F, K, and L represent data from mice subjected to maximal endurance testing. All data are shown as mean, and error bars indicate SD unless otherwise noted; p values indicate the significance of the difference by two-way ANOVA with Sidak multiple comparisons test between diets and treatment; significance is determined by p < 0.05. See also and .
Mouse Igg2b Myosin Heavy Chain Type I Antibody, supplied by Developmental Studies Hybridoma Bank, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse igg2b myosin heavy chain type i antibody/product/Developmental Studies Hybridoma Bank
Average 99 stars, based on 1 article reviews
mouse igg2b myosin heavy chain type i antibody - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

94
Vector Laboratories goat anti mouse igg2b igg dylight488
Inhibition of VEGFR signaling blocks increased endurance exercise capacity by SAAR (A) Fold changes of transcripts associated with Vegf signaling using transcriptomic dataset presented in in muscles of male mice ( n = 6) after sulfur amino acid restriction (SAAR) compared with control (Con) diet for seven days. (B) Normalized count values of Vegfb in EDL and soleus from bulk RNA sequencing ( n = 6) of male mice given ad libitum access to SAAR versus Con diet on day seven using transcriptomic dataset presented in . (C) Normalized count values of Flt1 in EDL and soleus from bulk RNA sequencing ( n = 6) of male mice given ad libitum access to SAAR versus Con diet on day seven using transcriptomic dataset presented in . (D) Experimental set up and color scheme used in E, 5F, C, and S5D. (E) Percent change in body weight ( n = 16–24) of male mice treated with vehicle (veh) or axitinib via oral gavage in combination with ad libitum access to SAAR versus Con diet after seven days. (F) Distance ran during a one-time maximal endurance test ( n = 16–24) of male mice treated with veh or axitinib via oral gavage in combination with ad libitum access to SAAR versus Con diet for seven days. (G) Representative fluorescence images of IB4 (white) staining in EDL cross sections of mice fed a Con or SAAR Diet, co-treated with veh or axitinib via oral gavage (scale bar, 400 μm) for seven days (n = 5–8). (H) Normalized count values of Flt1 in EDL treated with either veh or axitinib from bulk RNA sequencing ( n = 5) of male mice given ad libitum access to SAAR versus Con diet on day seven. (I) Normalized count values of Kdr in EDL treated with either veh or axitinib from bulk RNA sequencing ( n = 5) of male mice given ad libitum access to SAAR versus Con diet on day seven. (J) Experimental set up and color scheme used in K, 5L, J, and S5K. (K) Percent change in body weight (n = 8–10) of male mice treated with <t>IgG</t> or DC101 via i.p. injection every other day in combination with ad libitum access to SAAR versus Con diet after seven days. (L) Distance ran during a one-time maximal endurance test ( n = 12–16) of male mice treated with IgG or DC101 via i.p. injection every other day in combination with ad libitum access to SAAR versus Con diet on day seven. A-C, E, G-I, represent data from mice that were not subjected to endurance running; F, K, and L represent data from mice subjected to maximal endurance testing. All data are shown as mean, and error bars indicate SD unless otherwise noted; p values indicate the significance of the difference by two-way ANOVA with Sidak multiple comparisons test between diets and treatment; significance is determined by p < 0.05. See also and .
Goat Anti Mouse Igg2b Igg Dylight488, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/goat anti mouse igg2b igg dylight488/product/Vector Laboratories
Average 94 stars, based on 1 article reviews
goat anti mouse igg2b igg dylight488 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

99
Developmental Studies Hybridoma Bank myhci ba f8 alexa fluorotm 350 goat anti mouse igg2b
Inhibition of VEGFR signaling blocks increased endurance exercise capacity by SAAR (A) Fold changes of transcripts associated with Vegf signaling using transcriptomic dataset presented in in muscles of male mice ( n = 6) after sulfur amino acid restriction (SAAR) compared with control (Con) diet for seven days. (B) Normalized count values of Vegfb in EDL and soleus from bulk RNA sequencing ( n = 6) of male mice given ad libitum access to SAAR versus Con diet on day seven using transcriptomic dataset presented in . (C) Normalized count values of Flt1 in EDL and soleus from bulk RNA sequencing ( n = 6) of male mice given ad libitum access to SAAR versus Con diet on day seven using transcriptomic dataset presented in . (D) Experimental set up and color scheme used in E, 5F, C, and S5D. (E) Percent change in body weight ( n = 16–24) of male mice treated with vehicle (veh) or axitinib via oral gavage in combination with ad libitum access to SAAR versus Con diet after seven days. (F) Distance ran during a one-time maximal endurance test ( n = 16–24) of male mice treated with veh or axitinib via oral gavage in combination with ad libitum access to SAAR versus Con diet for seven days. (G) Representative fluorescence images of IB4 (white) staining in EDL cross sections of mice fed a Con or SAAR Diet, co-treated with veh or axitinib via oral gavage (scale bar, 400 μm) for seven days (n = 5–8). (H) Normalized count values of Flt1 in EDL treated with either veh or axitinib from bulk RNA sequencing ( n = 5) of male mice given ad libitum access to SAAR versus Con diet on day seven. (I) Normalized count values of Kdr in EDL treated with either veh or axitinib from bulk RNA sequencing ( n = 5) of male mice given ad libitum access to SAAR versus Con diet on day seven. (J) Experimental set up and color scheme used in K, 5L, J, and S5K. (K) Percent change in body weight (n = 8–10) of male mice treated with <t>IgG</t> or DC101 via i.p. injection every other day in combination with ad libitum access to SAAR versus Con diet after seven days. (L) Distance ran during a one-time maximal endurance test ( n = 12–16) of male mice treated with IgG or DC101 via i.p. injection every other day in combination with ad libitum access to SAAR versus Con diet on day seven. A-C, E, G-I, represent data from mice that were not subjected to endurance running; F, K, and L represent data from mice subjected to maximal endurance testing. All data are shown as mean, and error bars indicate SD unless otherwise noted; p values indicate the significance of the difference by two-way ANOVA with Sidak multiple comparisons test between diets and treatment; significance is determined by p < 0.05. See also and .
Myhci Ba F8 Alexa Fluorotm 350 Goat Anti Mouse Igg2b, supplied by Developmental Studies Hybridoma Bank, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/myhci ba f8 alexa fluorotm 350 goat anti mouse igg2b/product/Developmental Studies Hybridoma Bank
Average 99 stars, based on 1 article reviews
myhci ba f8 alexa fluorotm 350 goat anti mouse igg2b - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

99
Developmental Studies Hybridoma Bank mouse monoclonal igg2b anti mf20
Inhibition of VEGFR signaling blocks increased endurance exercise capacity by SAAR (A) Fold changes of transcripts associated with Vegf signaling using transcriptomic dataset presented in in muscles of male mice ( n = 6) after sulfur amino acid restriction (SAAR) compared with control (Con) diet for seven days. (B) Normalized count values of Vegfb in EDL and soleus from bulk RNA sequencing ( n = 6) of male mice given ad libitum access to SAAR versus Con diet on day seven using transcriptomic dataset presented in . (C) Normalized count values of Flt1 in EDL and soleus from bulk RNA sequencing ( n = 6) of male mice given ad libitum access to SAAR versus Con diet on day seven using transcriptomic dataset presented in . (D) Experimental set up and color scheme used in E, 5F, C, and S5D. (E) Percent change in body weight ( n = 16–24) of male mice treated with vehicle (veh) or axitinib via oral gavage in combination with ad libitum access to SAAR versus Con diet after seven days. (F) Distance ran during a one-time maximal endurance test ( n = 16–24) of male mice treated with veh or axitinib via oral gavage in combination with ad libitum access to SAAR versus Con diet for seven days. (G) Representative fluorescence images of IB4 (white) staining in EDL cross sections of mice fed a Con or SAAR Diet, co-treated with veh or axitinib via oral gavage (scale bar, 400 μm) for seven days (n = 5–8). (H) Normalized count values of Flt1 in EDL treated with either veh or axitinib from bulk RNA sequencing ( n = 5) of male mice given ad libitum access to SAAR versus Con diet on day seven. (I) Normalized count values of Kdr in EDL treated with either veh or axitinib from bulk RNA sequencing ( n = 5) of male mice given ad libitum access to SAAR versus Con diet on day seven. (J) Experimental set up and color scheme used in K, 5L, J, and S5K. (K) Percent change in body weight (n = 8–10) of male mice treated with <t>IgG</t> or DC101 via i.p. injection every other day in combination with ad libitum access to SAAR versus Con diet after seven days. (L) Distance ran during a one-time maximal endurance test ( n = 12–16) of male mice treated with IgG or DC101 via i.p. injection every other day in combination with ad libitum access to SAAR versus Con diet on day seven. A-C, E, G-I, represent data from mice that were not subjected to endurance running; F, K, and L represent data from mice subjected to maximal endurance testing. All data are shown as mean, and error bars indicate SD unless otherwise noted; p values indicate the significance of the difference by two-way ANOVA with Sidak multiple comparisons test between diets and treatment; significance is determined by p < 0.05. See also and .
Mouse Monoclonal Igg2b Anti Mf20, supplied by Developmental Studies Hybridoma Bank, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse monoclonal igg2b anti mf20/product/Developmental Studies Hybridoma Bank
Average 99 stars, based on 1 article reviews
mouse monoclonal igg2b anti mf20 - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

99
Developmental Studies Hybridoma Bank primary antibody mouse monoclonal igg2b anti mf20 dshb mf 20 if
Inhibition of VEGFR signaling blocks increased endurance exercise capacity by SAAR (A) Fold changes of transcripts associated with Vegf signaling using transcriptomic dataset presented in in muscles of male mice ( n = 6) after sulfur amino acid restriction (SAAR) compared with control (Con) diet for seven days. (B) Normalized count values of Vegfb in EDL and soleus from bulk RNA sequencing ( n = 6) of male mice given ad libitum access to SAAR versus Con diet on day seven using transcriptomic dataset presented in . (C) Normalized count values of Flt1 in EDL and soleus from bulk RNA sequencing ( n = 6) of male mice given ad libitum access to SAAR versus Con diet on day seven using transcriptomic dataset presented in . (D) Experimental set up and color scheme used in E, 5F, C, and S5D. (E) Percent change in body weight ( n = 16–24) of male mice treated with vehicle (veh) or axitinib via oral gavage in combination with ad libitum access to SAAR versus Con diet after seven days. (F) Distance ran during a one-time maximal endurance test ( n = 16–24) of male mice treated with veh or axitinib via oral gavage in combination with ad libitum access to SAAR versus Con diet for seven days. (G) Representative fluorescence images of IB4 (white) staining in EDL cross sections of mice fed a Con or SAAR Diet, co-treated with veh or axitinib via oral gavage (scale bar, 400 μm) for seven days (n = 5–8). (H) Normalized count values of Flt1 in EDL treated with either veh or axitinib from bulk RNA sequencing ( n = 5) of male mice given ad libitum access to SAAR versus Con diet on day seven. (I) Normalized count values of Kdr in EDL treated with either veh or axitinib from bulk RNA sequencing ( n = 5) of male mice given ad libitum access to SAAR versus Con diet on day seven. (J) Experimental set up and color scheme used in K, 5L, J, and S5K. (K) Percent change in body weight (n = 8–10) of male mice treated with <t>IgG</t> or DC101 via i.p. injection every other day in combination with ad libitum access to SAAR versus Con diet after seven days. (L) Distance ran during a one-time maximal endurance test ( n = 12–16) of male mice treated with IgG or DC101 via i.p. injection every other day in combination with ad libitum access to SAAR versus Con diet on day seven. A-C, E, G-I, represent data from mice that were not subjected to endurance running; F, K, and L represent data from mice subjected to maximal endurance testing. All data are shown as mean, and error bars indicate SD unless otherwise noted; p values indicate the significance of the difference by two-way ANOVA with Sidak multiple comparisons test between diets and treatment; significance is determined by p < 0.05. See also and .
Primary Antibody Mouse Monoclonal Igg2b Anti Mf20 Dshb Mf 20 If, supplied by Developmental Studies Hybridoma Bank, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/primary antibody mouse monoclonal igg2b anti mf20 dshb mf 20 if/product/Developmental Studies Hybridoma Bank
Average 99 stars, based on 1 article reviews
primary antibody mouse monoclonal igg2b anti mf20 dshb mf 20 if - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

99
Developmental Studies Hybridoma Bank mouse igg2b polyclonal anti myosin heavy chain type i
Inhibition of VEGFR signaling blocks increased endurance exercise capacity by SAAR (A) Fold changes of transcripts associated with Vegf signaling using transcriptomic dataset presented in in muscles of male mice ( n = 6) after sulfur amino acid restriction (SAAR) compared with control (Con) diet for seven days. (B) Normalized count values of Vegfb in EDL and soleus from bulk RNA sequencing ( n = 6) of male mice given ad libitum access to SAAR versus Con diet on day seven using transcriptomic dataset presented in . (C) Normalized count values of Flt1 in EDL and soleus from bulk RNA sequencing ( n = 6) of male mice given ad libitum access to SAAR versus Con diet on day seven using transcriptomic dataset presented in . (D) Experimental set up and color scheme used in E, 5F, C, and S5D. (E) Percent change in body weight ( n = 16–24) of male mice treated with vehicle (veh) or axitinib via oral gavage in combination with ad libitum access to SAAR versus Con diet after seven days. (F) Distance ran during a one-time maximal endurance test ( n = 16–24) of male mice treated with veh or axitinib via oral gavage in combination with ad libitum access to SAAR versus Con diet for seven days. (G) Representative fluorescence images of IB4 (white) staining in EDL cross sections of mice fed a Con or SAAR Diet, co-treated with veh or axitinib via oral gavage (scale bar, 400 μm) for seven days (n = 5–8). (H) Normalized count values of Flt1 in EDL treated with either veh or axitinib from bulk RNA sequencing ( n = 5) of male mice given ad libitum access to SAAR versus Con diet on day seven. (I) Normalized count values of Kdr in EDL treated with either veh or axitinib from bulk RNA sequencing ( n = 5) of male mice given ad libitum access to SAAR versus Con diet on day seven. (J) Experimental set up and color scheme used in K, 5L, J, and S5K. (K) Percent change in body weight (n = 8–10) of male mice treated with <t>IgG</t> or DC101 via i.p. injection every other day in combination with ad libitum access to SAAR versus Con diet after seven days. (L) Distance ran during a one-time maximal endurance test ( n = 12–16) of male mice treated with IgG or DC101 via i.p. injection every other day in combination with ad libitum access to SAAR versus Con diet on day seven. A-C, E, G-I, represent data from mice that were not subjected to endurance running; F, K, and L represent data from mice subjected to maximal endurance testing. All data are shown as mean, and error bars indicate SD unless otherwise noted; p values indicate the significance of the difference by two-way ANOVA with Sidak multiple comparisons test between diets and treatment; significance is determined by p < 0.05. See also and .
Mouse Igg2b Polyclonal Anti Myosin Heavy Chain Type I, supplied by Developmental Studies Hybridoma Bank, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse igg2b polyclonal anti myosin heavy chain type i/product/Developmental Studies Hybridoma Bank
Average 99 stars, based on 1 article reviews
mouse igg2b polyclonal anti myosin heavy chain type i - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

90
Jackson Immuno goat anti-rabbit alexa594 mouse igg2b 115-587-187
Inhibition of VEGFR signaling blocks increased endurance exercise capacity by SAAR (A) Fold changes of transcripts associated with Vegf signaling using transcriptomic dataset presented in in muscles of male mice ( n = 6) after sulfur amino acid restriction (SAAR) compared with control (Con) diet for seven days. (B) Normalized count values of Vegfb in EDL and soleus from bulk RNA sequencing ( n = 6) of male mice given ad libitum access to SAAR versus Con diet on day seven using transcriptomic dataset presented in . (C) Normalized count values of Flt1 in EDL and soleus from bulk RNA sequencing ( n = 6) of male mice given ad libitum access to SAAR versus Con diet on day seven using transcriptomic dataset presented in . (D) Experimental set up and color scheme used in E, 5F, C, and S5D. (E) Percent change in body weight ( n = 16–24) of male mice treated with vehicle (veh) or axitinib via oral gavage in combination with ad libitum access to SAAR versus Con diet after seven days. (F) Distance ran during a one-time maximal endurance test ( n = 16–24) of male mice treated with veh or axitinib via oral gavage in combination with ad libitum access to SAAR versus Con diet for seven days. (G) Representative fluorescence images of IB4 (white) staining in EDL cross sections of mice fed a Con or SAAR Diet, co-treated with veh or axitinib via oral gavage (scale bar, 400 μm) for seven days (n = 5–8). (H) Normalized count values of Flt1 in EDL treated with either veh or axitinib from bulk RNA sequencing ( n = 5) of male mice given ad libitum access to SAAR versus Con diet on day seven. (I) Normalized count values of Kdr in EDL treated with either veh or axitinib from bulk RNA sequencing ( n = 5) of male mice given ad libitum access to SAAR versus Con diet on day seven. (J) Experimental set up and color scheme used in K, 5L, J, and S5K. (K) Percent change in body weight (n = 8–10) of male mice treated with <t>IgG</t> or DC101 via i.p. injection every other day in combination with ad libitum access to SAAR versus Con diet after seven days. (L) Distance ran during a one-time maximal endurance test ( n = 12–16) of male mice treated with IgG or DC101 via i.p. injection every other day in combination with ad libitum access to SAAR versus Con diet on day seven. A-C, E, G-I, represent data from mice that were not subjected to endurance running; F, K, and L represent data from mice subjected to maximal endurance testing. All data are shown as mean, and error bars indicate SD unless otherwise noted; p values indicate the significance of the difference by two-way ANOVA with Sidak multiple comparisons test between diets and treatment; significance is determined by p < 0.05. See also and .
Goat Anti Rabbit Alexa594 Mouse Igg2b 115 587 187, supplied by Jackson Immuno, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/goat anti-rabbit alexa594 mouse igg2b 115-587-187/product/Jackson Immuno
Average 90 stars, based on 1 article reviews
goat anti-rabbit alexa594 mouse igg2b 115-587-187 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
AH Diagnostics rabbit anti-mouse igg2b
Inhibition of VEGFR signaling blocks increased endurance exercise capacity by SAAR (A) Fold changes of transcripts associated with Vegf signaling using transcriptomic dataset presented in in muscles of male mice ( n = 6) after sulfur amino acid restriction (SAAR) compared with control (Con) diet for seven days. (B) Normalized count values of Vegfb in EDL and soleus from bulk RNA sequencing ( n = 6) of male mice given ad libitum access to SAAR versus Con diet on day seven using transcriptomic dataset presented in . (C) Normalized count values of Flt1 in EDL and soleus from bulk RNA sequencing ( n = 6) of male mice given ad libitum access to SAAR versus Con diet on day seven using transcriptomic dataset presented in . (D) Experimental set up and color scheme used in E, 5F, C, and S5D. (E) Percent change in body weight ( n = 16–24) of male mice treated with vehicle (veh) or axitinib via oral gavage in combination with ad libitum access to SAAR versus Con diet after seven days. (F) Distance ran during a one-time maximal endurance test ( n = 16–24) of male mice treated with veh or axitinib via oral gavage in combination with ad libitum access to SAAR versus Con diet for seven days. (G) Representative fluorescence images of IB4 (white) staining in EDL cross sections of mice fed a Con or SAAR Diet, co-treated with veh or axitinib via oral gavage (scale bar, 400 μm) for seven days (n = 5–8). (H) Normalized count values of Flt1 in EDL treated with either veh or axitinib from bulk RNA sequencing ( n = 5) of male mice given ad libitum access to SAAR versus Con diet on day seven. (I) Normalized count values of Kdr in EDL treated with either veh or axitinib from bulk RNA sequencing ( n = 5) of male mice given ad libitum access to SAAR versus Con diet on day seven. (J) Experimental set up and color scheme used in K, 5L, J, and S5K. (K) Percent change in body weight (n = 8–10) of male mice treated with <t>IgG</t> or DC101 via i.p. injection every other day in combination with ad libitum access to SAAR versus Con diet after seven days. (L) Distance ran during a one-time maximal endurance test ( n = 12–16) of male mice treated with IgG or DC101 via i.p. injection every other day in combination with ad libitum access to SAAR versus Con diet on day seven. A-C, E, G-I, represent data from mice that were not subjected to endurance running; F, K, and L represent data from mice subjected to maximal endurance testing. All data are shown as mean, and error bars indicate SD unless otherwise noted; p values indicate the significance of the difference by two-way ANOVA with Sidak multiple comparisons test between diets and treatment; significance is determined by p < 0.05. See also and .
Rabbit Anti Mouse Igg2b, supplied by AH Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit anti-mouse igg2b/product/AH Diagnostics
Average 90 stars, based on 1 article reviews
rabbit anti-mouse igg2b - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

96
Cell Signaling Technology Inc 9359s ab 823649 mouse igg2b
Inhibition of VEGFR signaling blocks increased endurance exercise capacity by SAAR (A) Fold changes of transcripts associated with Vegf signaling using transcriptomic dataset presented in in muscles of male mice ( n = 6) after sulfur amino acid restriction (SAAR) compared with control (Con) diet for seven days. (B) Normalized count values of Vegfb in EDL and soleus from bulk RNA sequencing ( n = 6) of male mice given ad libitum access to SAAR versus Con diet on day seven using transcriptomic dataset presented in . (C) Normalized count values of Flt1 in EDL and soleus from bulk RNA sequencing ( n = 6) of male mice given ad libitum access to SAAR versus Con diet on day seven using transcriptomic dataset presented in . (D) Experimental set up and color scheme used in E, 5F, C, and S5D. (E) Percent change in body weight ( n = 16–24) of male mice treated with vehicle (veh) or axitinib via oral gavage in combination with ad libitum access to SAAR versus Con diet after seven days. (F) Distance ran during a one-time maximal endurance test ( n = 16–24) of male mice treated with veh or axitinib via oral gavage in combination with ad libitum access to SAAR versus Con diet for seven days. (G) Representative fluorescence images of IB4 (white) staining in EDL cross sections of mice fed a Con or SAAR Diet, co-treated with veh or axitinib via oral gavage (scale bar, 400 μm) for seven days (n = 5–8). (H) Normalized count values of Flt1 in EDL treated with either veh or axitinib from bulk RNA sequencing ( n = 5) of male mice given ad libitum access to SAAR versus Con diet on day seven. (I) Normalized count values of Kdr in EDL treated with either veh or axitinib from bulk RNA sequencing ( n = 5) of male mice given ad libitum access to SAAR versus Con diet on day seven. (J) Experimental set up and color scheme used in K, 5L, J, and S5K. (K) Percent change in body weight (n = 8–10) of male mice treated with <t>IgG</t> or DC101 via i.p. injection every other day in combination with ad libitum access to SAAR versus Con diet after seven days. (L) Distance ran during a one-time maximal endurance test ( n = 12–16) of male mice treated with IgG or DC101 via i.p. injection every other day in combination with ad libitum access to SAAR versus Con diet on day seven. A-C, E, G-I, represent data from mice that were not subjected to endurance running; F, K, and L represent data from mice subjected to maximal endurance testing. All data are shown as mean, and error bars indicate SD unless otherwise noted; p values indicate the significance of the difference by two-way ANOVA with Sidak multiple comparisons test between diets and treatment; significance is determined by p < 0.05. See also and .
9359s Ab 823649 Mouse Igg2b, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/9359s ab 823649 mouse igg2b/product/Cell Signaling Technology Inc
Average 96 stars, based on 1 article reviews
9359s ab 823649 mouse igg2b - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

99
Developmental Studies Hybridoma Bank mouse igg2b monoclonal anti mhc type i

Mouse Igg2b Monoclonal Anti Mhc Type I, supplied by Developmental Studies Hybridoma Bank, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse igg2b monoclonal anti mhc type i/product/Developmental Studies Hybridoma Bank
Average 99 stars, based on 1 article reviews
mouse igg2b monoclonal anti mhc type i - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

Image Search Results


Inhibition of VEGFR signaling blocks increased endurance exercise capacity by SAAR (A) Fold changes of transcripts associated with Vegf signaling using transcriptomic dataset presented in in muscles of male mice ( n = 6) after sulfur amino acid restriction (SAAR) compared with control (Con) diet for seven days. (B) Normalized count values of Vegfb in EDL and soleus from bulk RNA sequencing ( n = 6) of male mice given ad libitum access to SAAR versus Con diet on day seven using transcriptomic dataset presented in . (C) Normalized count values of Flt1 in EDL and soleus from bulk RNA sequencing ( n = 6) of male mice given ad libitum access to SAAR versus Con diet on day seven using transcriptomic dataset presented in . (D) Experimental set up and color scheme used in E, 5F, C, and S5D. (E) Percent change in body weight ( n = 16–24) of male mice treated with vehicle (veh) or axitinib via oral gavage in combination with ad libitum access to SAAR versus Con diet after seven days. (F) Distance ran during a one-time maximal endurance test ( n = 16–24) of male mice treated with veh or axitinib via oral gavage in combination with ad libitum access to SAAR versus Con diet for seven days. (G) Representative fluorescence images of IB4 (white) staining in EDL cross sections of mice fed a Con or SAAR Diet, co-treated with veh or axitinib via oral gavage (scale bar, 400 μm) for seven days (n = 5–8). (H) Normalized count values of Flt1 in EDL treated with either veh or axitinib from bulk RNA sequencing ( n = 5) of male mice given ad libitum access to SAAR versus Con diet on day seven. (I) Normalized count values of Kdr in EDL treated with either veh or axitinib from bulk RNA sequencing ( n = 5) of male mice given ad libitum access to SAAR versus Con diet on day seven. (J) Experimental set up and color scheme used in K, 5L, J, and S5K. (K) Percent change in body weight (n = 8–10) of male mice treated with IgG or DC101 via i.p. injection every other day in combination with ad libitum access to SAAR versus Con diet after seven days. (L) Distance ran during a one-time maximal endurance test ( n = 12–16) of male mice treated with IgG or DC101 via i.p. injection every other day in combination with ad libitum access to SAAR versus Con diet on day seven. A-C, E, G-I, represent data from mice that were not subjected to endurance running; F, K, and L represent data from mice subjected to maximal endurance testing. All data are shown as mean, and error bars indicate SD unless otherwise noted; p values indicate the significance of the difference by two-way ANOVA with Sidak multiple comparisons test between diets and treatment; significance is determined by p < 0.05. See also and .

Journal: iScience

Article Title: Angiogenesis-independent VEGF signaling enhances exercise capacity by increasing fat oxidation in mice fed sulfur amino acid-restricted diets

doi: 10.1016/j.isci.2025.114148

Figure Lengend Snippet: Inhibition of VEGFR signaling blocks increased endurance exercise capacity by SAAR (A) Fold changes of transcripts associated with Vegf signaling using transcriptomic dataset presented in in muscles of male mice ( n = 6) after sulfur amino acid restriction (SAAR) compared with control (Con) diet for seven days. (B) Normalized count values of Vegfb in EDL and soleus from bulk RNA sequencing ( n = 6) of male mice given ad libitum access to SAAR versus Con diet on day seven using transcriptomic dataset presented in . (C) Normalized count values of Flt1 in EDL and soleus from bulk RNA sequencing ( n = 6) of male mice given ad libitum access to SAAR versus Con diet on day seven using transcriptomic dataset presented in . (D) Experimental set up and color scheme used in E, 5F, C, and S5D. (E) Percent change in body weight ( n = 16–24) of male mice treated with vehicle (veh) or axitinib via oral gavage in combination with ad libitum access to SAAR versus Con diet after seven days. (F) Distance ran during a one-time maximal endurance test ( n = 16–24) of male mice treated with veh or axitinib via oral gavage in combination with ad libitum access to SAAR versus Con diet for seven days. (G) Representative fluorescence images of IB4 (white) staining in EDL cross sections of mice fed a Con or SAAR Diet, co-treated with veh or axitinib via oral gavage (scale bar, 400 μm) for seven days (n = 5–8). (H) Normalized count values of Flt1 in EDL treated with either veh or axitinib from bulk RNA sequencing ( n = 5) of male mice given ad libitum access to SAAR versus Con diet on day seven. (I) Normalized count values of Kdr in EDL treated with either veh or axitinib from bulk RNA sequencing ( n = 5) of male mice given ad libitum access to SAAR versus Con diet on day seven. (J) Experimental set up and color scheme used in K, 5L, J, and S5K. (K) Percent change in body weight (n = 8–10) of male mice treated with IgG or DC101 via i.p. injection every other day in combination with ad libitum access to SAAR versus Con diet after seven days. (L) Distance ran during a one-time maximal endurance test ( n = 12–16) of male mice treated with IgG or DC101 via i.p. injection every other day in combination with ad libitum access to SAAR versus Con diet on day seven. A-C, E, G-I, represent data from mice that were not subjected to endurance running; F, K, and L represent data from mice subjected to maximal endurance testing. All data are shown as mean, and error bars indicate SD unless otherwise noted; p values indicate the significance of the difference by two-way ANOVA with Sidak multiple comparisons test between diets and treatment; significance is determined by p < 0.05. See also and .

Article Snippet: Mouse (IgG2b) Myosin Heavy Chain Type I antibody (BA-F8) , DSHB , Cat# BA-F8; RRID: AB_10572253.

Techniques: Inhibition, Muscles, Control, RNA Sequencing, Fluorescence, Staining, Injection

Journal: Cell Reports Medicine

Article Title: Impact of physical activity on physical function, mitochondrial energetics, ROS production, and Ca 2+ handling across the adult lifespan in men

doi: 10.1016/j.xcrm.2025.101968

Figure Lengend Snippet:

Article Snippet: Muscle sections were then incubated for 1 h, at room temperature with the following primary antibodies mix: a mouse IgG2b monoclonal anti-MHC type I (BA-F8, 1:25, DSHB, Iowa, IA, USA), a mouse IgG1 monoclonal anti-MHC type IIa (Sc-71, 1:200, DSHB, Iowa, IA, USA), a mouse IgM monoclonal anti-MHC type IIx (6-H1, 1:25, DSHB, Iowa, IA, USA) and a rabbit IgG polyclonal anti-laminin (Sigma, L9393, 1:750) diluted in PBS containing 10% of GS.

Techniques: Muscles, Recombinant, Saline, Software, Sterility, Microscopy, Adhesive, Stripping Membranes